Androgenetic alopecia is not an autoimmune disease. It is a hormone-driven, genetically determined form of hair loss, fundamentally different from autoimmune conditions like alopecia areata. The confusion between the two is understandable because both cause hair loss and both involve some degree of inflammation at the follicle level, but the underlying mechanisms are distinct.
What Actually Causes Androgenetic Alopecia
Androgenetic alopecia (AGA) is driven by androgens, specifically a potent form of testosterone called DHT. In people with a genetic susceptibility, DHT binds to receptors in scalp hair follicles and triggers a cascade of damage. The follicle’s base cells release a protein that causes programmed cell death in the outer layer of the hair root. At the same time, DHT disrupts the signaling pathways that hair follicle stem cells rely on to grow and regenerate.
The damage compounds over time. DHT stimulation causes the tiny blood vessels feeding the follicle to degrade and calcify, steadily reducing blood flow. As blood supply drops, the follicle spends less and less time in its active growth phase. Each cycle produces a thinner, shorter hair until the follicle eventually miniaturizes to the point where it produces only fine, nearly invisible vellus hair, or stops producing visible hair altogether.
This is the most common form of hair loss in humans. Roughly 30% of men show signs by their 30s, and up to 80% of men and 50% of women develop some degree of it by age 70.
How Autoimmune Hair Loss Works Differently
Alopecia areata, the autoimmune form of hair loss, has a completely different mechanism. In alopecia areata, a specific type of immune cell (cytotoxic T cells) attacks hair follicles directly. These T cells swarm the follicle, producing inflammatory signals that collapse the follicle’s natural immune protection and create a self-reinforcing cycle of damage. The inflammatory compounds they release recruit even more immune cells, intensifying the assault.
The key distinction is what starts the process. In alopecia areata, the immune system mistakenly identifies the hair follicle as a threat and launches a targeted attack. In androgenetic alopecia, there is no immune system malfunction. The follicle shrinks because it is responding to a hormone, DHT, exactly the way its genetic programming dictates. The immune system is not attacking anything.
This difference is visible under a dermatoscope, too. Alopecia areata typically produces well-defined, round patches of complete hair loss with distinctive “exclamation point” hairs at the borders. Androgenetic alopecia produces a gradual, patterned thinning with a mix of normal and miniaturized hairs. In women, dermatoscopic examination reveals that more than 10% of hairs in affected areas are thinner than 0.03 mm, compared to about 6% in a healthy scalp. The ratio of thin hairs in the front of the scalp versus the back is one of the key diagnostic markers.
The Inflammation Overlap That Causes Confusion
One reason people wonder whether AGA is autoimmune is that inflammation does play a supporting role in the condition. Scalp biopsies from people with early androgenetic alopecia sometimes show mild lymphocytic infiltration around follicles, a feature called the “peripilar sign” visible on dermatoscopy as a discoloration of the skin around follicle openings. DHT-driven chemical signaling in the scalp can attract some immune cells to the area.
But this low-grade, secondary inflammation is nothing like the dense, targeted immune attack seen in alopecia areata. In AGA, inflammation is a byproduct of the hormonal process, not the cause. It may contribute to ongoing follicle damage, but removing the inflammation alone would not stop the hair loss. Blocking DHT or its effects on the follicle would.
Genetics Point to Hormones, Not Immunity
The genetic architecture of AGA further confirms its hormonal nature. The strongest genetic associations are with the androgen receptor gene on the X chromosome and a region on chromosome 20. Both relate directly to how the body processes and responds to androgens. Other risk genes involve pathways that control hair follicle growth signaling, programmed cell death, and the enzyme that converts testosterone into DHT.
Large genetic studies have also identified genes linked to blood vessel oxygen-sensing pathways and growth factor signaling inhibitors, consistent with the vascular degradation seen in balding follicles. None of the major risk genes for AGA overlap with the immune system pathways implicated in alopecia areata or other autoimmune diseases. The genetic blueprints of these two conditions point in entirely different directions.
Treatments Reflect the Difference
The treatments that work for each condition reinforce the distinction. The two FDA-approved drugs for androgenetic alopecia are topical minoxidil and oral finasteride. Minoxidil works by dilating blood vessels around the follicle and promoting cell growth. Finasteride blocks the enzyme that converts testosterone to DHT, reducing DHT levels by targeting the hormonal root cause. Both show measurable improvement, with finasteride improving hair growth within the first year and continuing to show benefit for up to 10 years of use.
Alopecia areata, by contrast, is now treated with JAK inhibitors, drugs that suppress the specific immune signaling pathways that drive the T cell attack on follicles. Three JAK inhibitors (baricitinib, ritlecitinib, and deuruxolitinib) have received FDA approval specifically for severe alopecia areata. These drugs have no established role in treating androgenetic alopecia, because there is no aberrant immune response to suppress.
If AGA were autoimmune, you would expect immunosuppressive therapies to help. They don’t. And if alopecia areata were hormonal, you would expect DHT blockers to help. They don’t either. The treatments that work for each condition are essentially proof of what drives them.
AGA’s Link to Metabolic Health
While androgenetic alopecia is not autoimmune, it is not purely cosmetic either. A large meta-analysis found that people with AGA are about 3.5 times more likely to have metabolic syndrome, a cluster of conditions including excess abdominal fat, high blood pressure, elevated blood sugar, and abnormal cholesterol levels. People with AGA in the studies consistently showed higher BMI, larger waist circumference, higher fasting blood sugar, higher triglycerides, and lower levels of protective HDL cholesterol compared to controls.
The link appears to run in both directions. High androgen levels can promote changes in blood vessel walls and disrupt cholesterol balance. At the same time, insulin resistance and elevated insulin can increase local androgen production in the scalp, potentially accelerating hair loss. Women, people with early-onset AGA, and people of African descent showed especially strong associations with metabolic syndrome in the data. This connection is worth being aware of, not because AGA causes heart disease, but because the same hormonal environment that drives the hair loss can also affect cardiovascular and metabolic health over time.